Lu Xie, MD (she/her/hers)

consultant and vice director of Musculoskeletal Tumor Center
Peking University People's Hospital, China (People's Republic)

Medical Education
Peking University Medical College (Department of Clinical Medicine, Peking University), Beijing, China 2003-2011 Doctor of Clinical Medicine (8-year doctoral program)

Study Overseas Experience
Gil hospital of Gachon University of Medicine and Science in South Korea 2007.7-2007.8 Clerkship for breast cancer center
Mayo Clinic Cancer Center in U.S.A. 2016.9-2016.12 Clinical visitor for sarcoma


Interests
Target therapy for orthopedic tumors
Immunotherapy for osteosarcoma

Poster(s):

• (P 51) OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA

• (P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS

• (P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP

• (P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL

• (P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY